SANTA CLARA, Calif.--(BUSINESS WIRE)--Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, today announced that John Dahldorf has joined the company as chief financial officer. Most recently Dahldorf was chief financial officer at Volcano Corporation.
As chief financial officer at Benvenue Medical, Dahldorf will partner with the senior management team to help shape the company’s long-term strategy and ensure capital needs are met.
“I was looking for a great management team and a portfolio of medical technology that has strong growth potential, and I found it in Benvenue Medical,” Dahldorf said. “Benvenue’s products, Luna and Kiva, have entered a $3.2 billion U.S. market that’s historically had very little innovation. I believe Benvenue has potential similar to what I experienced at Volcano, where we grew from virtually zero to $400 million in 11 years.”
“John brings invaluable experience with private and public companies, including being chief financial officer at a publicly traded company,” said Robert Weigle, CEO of Benvenue Medical, Inc. “His strong reputation, experience in the investment community and expertise in public markets will be advantageous for achieving our future business plans.”
Dahldorf brings more than 30 years of financial, operational and leadership experience in the healthcare industry to Benvenue Medical. In his tenure at Volcano Corporation, he oversaw all aspects of the finance, accounting and information technology functions for the medical device company. Previous experience includes co-chief executive officer and chief financial officer at Digirad Corporation; finance director at Arrow Electronics; and a number of leadership positions at Baxter companies. He earned his master of business administration and bachelor of finance degrees at Western Illinois University.
About Benvenue Medical, Inc.
Founded in 2004, Benvenue Medical, Inc. provides next generation minimally invasive systems for spine repair that combine expandable implants with novel delivery instruments to provide enduring functional benefits for patients. The company is privately held and funded by InterWest Partners, Versant Ventures, DeNovo Ventures, Domain Associates and Technology Partners. Its first products are designed for the treatment of vertebral compression fractures and degenerative disc disease, which have combined revenues of $9 billion globally. For more information, visit www.benvenuemedical.com.